During the last session, Actinium Pharmaceuticals Inc (AMEX:ATNM)’s traded shares were 0.43 million, with the beta value of the company hitting 0.10. At the end of the trading day, the stock’s price was $1.23, reflecting an intraday loss of -1.60% or -$0.02. The 52-week high for the ATNM share is $10.24, that puts it down -732.52 from that peak though still a striking 3.25% gain since the share price plummeted to a 52-week low of $1.19. The company’s market capitalization is $38.37M, and the average intraday trading volume over the past 10 days was 0.36 million shares, and the average trade volume was 285.93K shares over the past three months.
Actinium Pharmaceuticals Inc (ATNM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. ATNM has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.39.
Actinium Pharmaceuticals Inc (AMEX:ATNM) trade information
Actinium Pharmaceuticals Inc (ATNM) registered a -1.60% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.60% in intraday trading to $1.23, hitting a weekly high. The stock’s 5-day price performance is -9.56%, and it has moved by -28.07% in 30 days. Based on these gigs, the overall price performance for the year is -76.21%. The short interest in Actinium Pharmaceuticals Inc (AMEX:ATNM) is 1.45 million shares and it means that shorts have 5.72 day(s) to cover.
The consensus price target of analysts on Wall Street is $4.47, which implies an increase of 72.48% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $4.95 respectively. As a result, ATNM is trading at a discount of -302.44% off the target high and -225.2% off the low.
Actinium Pharmaceuticals Inc (ATNM) estimates and forecasts
Statistics show that Actinium Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Actinium Pharmaceuticals Inc (ATNM) shares have gone down -84.27% during the last six months, with a year-to-date growth rate more than the industry average at 22.95% against 16.40. In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.80%. While earnings are projected to return 22.73% in 2024.
ATNM Dividends
Actinium Pharmaceuticals Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Actinium Pharmaceuticals Inc (AMEX:ATNM)’s Major holders
Actinium Pharmaceuticals Inc insiders own 1.79% of total outstanding shares while institutional holders control 30.11%, with the float percentage being 30.66%.
